Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 661-666 , July 2006

Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19)

  • Nicolas Spaeth

      Affiliations

    • PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Matthias T. Wyss

      Affiliations

    • PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Jens Pahnke

      Affiliations

    • Department of Pathology, University Hospital Zurich, 8091 Zurich, Switzerland
    • Department of Neurology, Rostock University, 18147 Rostock, Germany
    • ,
  • Gregoire Biollaz

      Affiliations

    • Section of Clinical Immunology, University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Eveline Trachsel

      Affiliations

    • Department of Applied Biosciences, Swiss Federal Institute of Technology, 8093 Zurich, Switzerland
    • ,
  • Konstantin Drandarov

      Affiliations

    • Center for Radiopharmaceutical Science of ETH, PSI and USZ, ETH Hoenggerberg Zurich and University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Valerie Treyer

      Affiliations

    • PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Bruno Weber

      Affiliations

    • PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    • ,
  • Dario Neri

      Affiliations

    • Department of Applied Biosciences, Swiss Federal Institute of Technology, 8093 Zurich, Switzerland
    • ,
  • Alfred Buck

      Affiliations

    • PET Center, Division of Nuclear Medicine, University Hospital Zurich, 8091 Zurich, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 44 255 35 47; fax: +41 44 255 44 14.

Received 23 March 2006 ,Revised 3 May 2006 ,Accepted 8 May 2006.

References 

  1. DeAngelis LM. Brain tumors. N Engl J Med. 2001;344:114–123
  2. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, et al. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur J Nucl Med. 1999;26:348–357
  3. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27:601–609
  4. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2002;20:1389–1397
  5. Goetz C, Rachinger W, Poepperl G, Decker M, Gildehaus FJ, Stocker S, et al. Intralesional radioimmunotherapy in the treatment of malignant glioma: clinical and experimental findings. Acta Neurochir Suppl. 2003;88:69–75
  6. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–911
  7. Popperl G, Gotz C, Gildehaus FJ, Yousry TA, Reulen HJ, Hahn K, et al. Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Nuklearmedizin. 2002;41:120–128
  8. Mayr MT, Crocker IR, Butker EK, Williams H, Cotsonis GA, Olson JJ. Results of interstitial brachytherapy for malignant brain tumors. Int J Oncol. 2002;21:817–823
  9. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashley SE, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37(2):393–398
  10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186
  11. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer. 2005;5:436–446
  12. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, et al. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J. 1987;6:2337–2342
  13. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769–21776
  14. Viti F, Tarli L, Giovannoni L, Zardi L, Neri D. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis. Cancer Res. 1999;59:347–352
  15. Tarli L, Balza E, Viti F, Borsi L, Castellani P, Berndorff D, et al. A high-affinity human antibody that targets tumoral blood vessels. Blood. 1999;94:192–198
  16. Demartis S, Tarli L, Borsi L, Zardi L, Neri D. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin. Eur J Nucl Med. 2001;28:534–539
  17. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75–85
  18. Berndorff D, Borkowski S, Sieger S, Rother A, Friebe M, Viti F, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate. Clin Cancer Res. 2005;11:7053s–7063s
  19. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571–579
  20. Castellani P, Borsi L, Carnemolla B, Biro A, Dorcaratto A, Viale GL, et al. Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol. 2002;161:1695–1700
  21. Greenwood FC, Hunter WM, Glover JS. The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J. 1963;89:114–123
  22. Ambar BB, Frei K, Malipiero U, Morelli AE, Castro MG, Lowenstein PR, et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. Hum Gene Ther. 1999;10:1641–1648
  23. Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol. 2003;179:521–526
  24. Mariani G, Lasku A, Pau A, Villa G, Motta C, Calcagno G, et al. A pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumors. Cancer. 1997;80:2484–2489
  25. Kondziolka D, Lunsford LD, Claassen D, Pandalai S, Maitz AH, Flickinger JC. Radiobiology of radiosurgery: Part II. The rat C6 glioma model. Neurosurgery. 1992;31:280–288
  26. Kondziolka D, Somaza S, Comey C, Lunsford LD, Claassen D, Pandalai S, et al. Radiosurgery and fractionated radiation therapy: comparison of different techniques in an in vivo rat glioma model. J Neurosurg. 1996;84:1033–1038
  27. Kondziolka D, Mori Y, Martinez AJ, McLaughlin MR, Flickinger JC, Lunsford LD. Beneficial effects of the radioprotectant 21-aminosteroid U-74389G in a radiosurgery rat malignant glioma model. Int J Radiat Oncol Biol Phys. 1999;44:179–184
  28. Grobben B, De Deyn PP, Slegers H. Rat C6 glioma as experimental model system for the study of glioblastoma growth and invasion. Cell Tissue Res. 2002;310:257–270
  29. Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998;36:91–102
  30. Beutler AS, Banck MS, Wedekind D, Hedrich HJ. Tumor gene therapy made easy: allogeneic major histocompatibility complex in the C6 rat glioma model. Hum Gene Ther. 1999;10:95–101
  31. Mairs RJ, Wideman CL, Angerson WJ, Whateley TL, Reza MS, Reeves JR, et al. Comparison of different methods of intracerebral administration of radioiododeoxyuridine for glioma therapy using a rat model. Br J Cancer. 2000;82:74–80
  32. Watanabe K, Sakamoto M, Somiya M, Amin MR, Kamitani H, Watanabe T. Feasibility and limitations of the rat model by C6 gliomas implanted at the subcutaneous region. Neurol Res. 2002;24:485–490
  33. Parsa AT, Chakrabarti I, Hurley PT, Chi JH, Hall JS, Kaiser MG, et al. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Neurosurgery. 2000;47:993–1000

PII: S0969-8051(06)00091-6

doi: 10.1016/j.nucmedbio.2006.05.001

Nuclear Medicine and Biology
Volume 33, Issue 5 , Pages 661-666 , July 2006

Article Tools

* Image Usage & Resolution